Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
WREYP1q4ke8gLPSW
